6-(2-Methylpropyl)-2-azaspiro[3.3]heptane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 6-(2-Methylpropyl)-2-azaspiro[3.3]heptane
• 英文别名: 6-(2-methylpropyl)-2-azaspiro[3.3]heptane
• 化学式: C₁₀H₁₉N
• 分子量: 153.26
• InChiKey: XNYLWVHZDNYGTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• CONDENSED TRICYCLIC COMPOUND USED AS KINASE INHIBITOR
  申请人：Hangzhou Innogate Pharma Co., Ltd.

  公开号：US20220153766A1

  公开（公告）日：2022-05-19

  The present invention provides a class of compounds containing tricyclic heteroaryl groups. Specifically, the present invention provides compounds of the structure represented by the following formula (I) (the definition of each group is as described in the specification), pharmaceutical compositions containing the compounds of formula (I), as well as isotopic derivatives of these compounds, chiral isomers, allosteric forms, different salts, prodrugs, formulations, etc. The compounds of formula (I) can effectively inhibit protein kinases (including EGFR, EGFR (C797S), ALK, and HPK1, etc.), thereby playing a role in the treatment of various tumors.

  本发明提供了一类含有三环杂芳基团的化合物。具体来说，本发明提供了以下式子（I）所表示的结构的化合物（每个基团的定义如说明书所述），含有式子（I）化合物的制药组合物，以及这些化合物的同位素衍生物、手性异构体、异构形式、不同的盐、前药、配方等。式子（I）化合物可以有效抑制蛋白激酶（包括EGFR、EGFR（C797S）、ALK和HPK1等），从而在治疗各种肿瘤方面发挥作用。
• Compound containing tricyclic heteroaryl group
  申请人：Hangzhou Innogate Pharma Co., Ltd.

  公开号：US10968234B2

  公开（公告）日：2021-04-06

  A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosteries, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.

  本发明提供了一类含有三环杂芳基的化合物。具体来说，本发明提供了下式（I）所代表结构的化合物（各基团如说明书中所定义）、含有式（I）化合物的药物组合物，以及它们的同位素衍生物、手性异构体、异构体、不同的盐、原药、制剂等。它能有效抑制蛋白激酶（如表皮生长因子受体、FAK、SYK、FLT-3、Axl、CDK、JAK 等），从而治疗各种肿瘤、非酒精性肝病（NASH）、肺纤维化（IPF）及相关的多种疾病。
• Heterocycles useful as anti-cancer agents
  申请人：Hangzhou Innogate Pharma Co., Ltd.

  公开号：US11225492B2

  公开（公告）日：2022-01-18

  The present invention provides compounds of Formula (I), and the pharmaceutically acceptable salts, hydrates, and solvates thereof. It also provides pharmaceutical compositions, preparation and utilities thereof in treating diseases and disorders including cancers.

  本发明提供了式（I）化合物及其药学上可接受的盐、水合物和溶液。本发明还提供了用于治疗包括癌症在内的疾病和失调的药物组合物、制备方法和用途。
• COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP
  申请人：Hangzhou Innogate Pharma Co., Ltd.

  公开号：US20200354376A1

  公开（公告）日：2020-11-12

  A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosteries, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.
• COMPOUND AS IRAK INHIBITOR
  申请人：SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD.

  公开号：US20220204473A1

  公开（公告）日：2022-06-30

  The present disclosure relates a compound as an IRAK inhibitor. Specifically, the present disclosure provides a compound of formula I, or a cis-trans isomer, an optical isomer, a racemate, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative thereof, a hydrate or a solvate thereof. The compounds disclosed herein have potent inhibitory effects on IRAK and thus have therapeutic effect on IRAK-related diseases.